A5031293399- CAR-T cell therapy research
- Virus-based gene therapy research
- Multiple Myeloma Research and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Biosimilars and Bioanalytical Methods
- Hematopoietic Stem Cell Transplantation
- Prostate Cancer Treatment and Research
- CRISPR and Genetic Engineering
- Carbohydrate Chemistry and Synthesis
- Immunotherapy and Immune Responses
- Integrated Circuits and Semiconductor Failure Analysis
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- Advancements in Semiconductor Devices and Circuit Design
- Cancer Immunotherapy and Biomarkers
- HIV Research and Treatment
- Spinal Cord Injury Research
- Nanowire Synthesis and Applications
- Lymphoma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Spinal Dysraphism and Malformations
University of Wisconsin–Madison
2024-2025
University of Wisconsin Carbone Cancer Center
2024-2025
Beike Biotechnology (China)
2023-2024
AvantGen (United States)
2023-2024
Memorial Sloan Kettering Cancer Center
2006-2024
Fudan University
2023-2024
Shanghai Pulmonary Hospital
2017-2024
Tongji University
2013-2024
Zhejiang University
2023
Krembil Research Institute
2019
Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD7 chimeric antigen receptor (CAR) safety efficacy in patients r/r T-ALL.In this single-center, phase I trial, we administered CAR T cells, manufactured from either previous stem-cell transplantation donors new donors, T-ALL, single infusions at doses of 5 × 105 1 106 (±30%) cells per kilogram body weight. primary end point...
Abstract Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell in 34 relapsed or refractory (r/r) B-ALL pediatric adult patients who failed from previous therapy. Complete remission (CR) CR incomplete count recovery (CRi) was achieved 24 30 (80%) that could evaluated on day infusion, which accounted for 70.5% all enrolled patients. Most only...
Abstract Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for hematologic malignancies, however, response rates and associated immune-related adverse effects widely vary among patients. Here we show, by comparing diversity composition of the gut microbiome during different CAR-T therapeutic phases in clinical trial ChiCTR1800017404, that flora characteristically differs patients according to treatment stages, might also reflect patient...
G protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM.This phase Ⅱ, single-arm study enrolled (18-70 years) R/R MM. Lymphodepletion was performed before received 2 × 106/kg CAR cells. The primary end point proportion who achieved an overall response....
Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (r/r T-ALL), a previous phase I trial report, at median follow-up of 6.3 months. Here we report long-term safety activity the therapy after 2-year follow-up.Participants received CAR derived from prior stem cell transplantation (SCT) donors HLA-matched new lymphodepletion. The target dose was 1 × 106 (± 30%) per...
Abstract Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for malignancies but also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 cells using endoplasmic reticulum retention have shown efficacy patients with acute lymphoblastic leukemia (ALL). Here we launched a phase I trial explore differences between autologous and allogeneic therapies ALL lymphoma. Ten were treated 5 received...
CD19-targeting chimeric antigen receptor (CAR)-T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) but been associated serious adverse effects, such as cytokine release syndrome (CRS). It speculated that NHL baseline disease burden might affect clinical outcome and CRS, this not explored detail any previous study. Metabolic tumor volume (MTV) total lesion glycolysis (TLG), measured by fluorodeoxyglucose positron emission tomography/computed...
Abstract The prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic transplantation is dismal when treated with conventional approaches. While single‐target CD19 or CD22 chimeric antigen receptor (CAR) T‐cell therapy has achieved high complete remission (CR) rates in refractory/relapsed B‐ALL, it could not maintain a durable most patients. To prolong relapse‐free survival, we sequentially combined and CAR‐T cells to treat post‐transplant B‐ALL patients both CD19/CD22...
Abstract Background Consolidative allogeneic hematopoietic stem cell transplantation is a controversial option for patients with relapsed/refractory acute lymphoblastic leukemia after chimeric antigen receptor T (CAR-T) therapy. We performed multicenter retrospective study to assess whether can benefit from haploidentical CAR-T Methods A total of 122 therapy were enrolled, including 67 without subsequent (non-transplant group) and 55 (transplant group). Long-term outcome was assessed, as its...
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity are two major CAR T related toxicities. With the interventions of Tocilizumab steroids, many patients can recover from severe CRS. However, some refractory to steroids develop life-threatening consequences. Ruxolitinib is an oral JAKs inhibitor promising drug in inflammatory diseases. In this pilot study, we evaluate efficacy Of 14 r/r B-ALL children who received CD19 or CD22 cell therapies, 4 developed (≥grade...
Chimeric antigen receptor (CAR) T-cell therapies that target either CD19 or CD22 alone have potent antilymphoma effects. However, escape-mediated relapse often occurs. CAR T cells targeting both and may overcome this limitation. In study, we developed bispecific simultaneously recognizing CD19- CD22-expressing targets assessed their safety efficacy profiles in patients with relapsed/refractory aggressive B-cell lymphoma. Twenty-four were screened, 16 found eligible for the study....
Although chimeric antigen receptor T (CAR-T) cell therapy has proven to be effective in treating relapsed or refractory B-cell hematological malignancies, severe toxicities remain an intractable issue. This retrospective study assessed the characteristics and risk factors of new-onset cytopenia following CAR-T infusion 76 patients with r/r acute lymphoblastic leukemia. The rates were high, including neutropenia (SN) (39/56, 70%), anemia (SA) (35/66, 53%), thrombocytopenia (ST) (31/64, 48%)....
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of hematological malignancies due to prominent anti-tumor effects. B maturation (BCMA) CAR-T cells have demonstrated promising effects in patients with relapsed/refractory multiple myeloma. However, dynamics proliferation and cytotoxicity remains unexplored. Here, we longitudinally profiled transcriptomes 55,488 including products, cells, endogenous at peak remission phases a plasma leukemia (PCL)...
Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) is overexpressed in more than 90% of non-small cell lung cancer (NSCLC) but not significantly normal tissue. It therefore an important tumor antigen target for chimeric receptors (CAR)-T-based therapy NSCLC. Here, we developed a specific CAR targeted to EphA2, and the anti-tumor effects this were investigated. A second generation with co-stimulatory receptor 4-1BB EphA2 was developed. The functionality EphA2-specific T cells vitro...
Abstract Single antigen–targeted chimeric antigen receptor (CAR) T-cell therapy may be insufficient to induce a durable response in pediatric aggressive B-cell lymphomas. This clinical trial examined the feasibility of sequential different CAR for relapsed/refractory (R/R) Burkitt lymphoma. Twenty-three patients received first CD19 infusion. The who did not achieve an ongoing complete (CR) underwent 1 or more infusions that targeted CD22 followed by CD20 according their disease status and...
Background Murine chimeric antigen receptor T (CAR-T) cell therapy has demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, the potential immunogenicity of murine single-chain variable fragment domain may limit persistence CAR-T cell, leading to relapse. Methods We performed a trial determine safety and efficacy autologous allogeneic humanized CD19-targeted (hCART19) for R/R B-ALL. Fifty-eight (aged 13–74 years) were...
256 Background: Resistance to Androgen Receptor Pathway Inhibitors (ARPI) in metastatic prostate cancer (mPC) is universal and can be driven by complex genomic alterations. The evolution of lineage state transitions from adenocarcinomas neuroendocrine (NEPC) has also been shown drive treatment resistance poor survival. Identifying the timing association mutations with limited need for serial tumor biopsies. We report an integrated analysis clinical next-generation sequencing (NGS) data mPC...
Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis prognostic gene expression pathways has been limited. Therefore, we aggregated cohort 1012 mCRPC tissue samples from 769 patients and investigated the association expression‐based with clinical outcomes intrapatient intratumor heterogeneity. Survival data were obtained for 272 patients. Pathway‐level enrichment was...